TNFSF10 and breast carcinoma: We used the breast cancer cell lines used in Fig. 2, which are known to have different responses to TRAIL-based treatments: MCF10A and MDA-MB-231 are TRAIL-sensitive (33), whereas MCF 7 is TRAIL-resistant (33).